189 related articles for article (PubMed ID: 11355862)
1. Coumarin substrates for cytochrome P450 2D6 fluorescence assays.
Nakamura K; Hanna IH; Cai H; Nishimura Y; Williams KM; Guengerich FP
Anal Biochem; 2001 May; 292(2):280-6. PubMed ID: 11355862
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening.
Onderwater RC; Venhorst J; Commandeur JN; Vermeulen NP
Chem Res Toxicol; 1999 Jul; 12(7):555-9. PubMed ID: 10409393
[TBL] [Abstract][Full Text] [Related]
3. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity.
Venhorst J; Onderwater RC; Meerman JH; Commandeur JN; Vermeulen NP
Drug Metab Dispos; 2000 Dec; 28(12):1524-32. PubMed ID: 11095593
[TBL] [Abstract][Full Text] [Related]
4. The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition.
Bonn B; Masimirembwa CM; Aristei Y; Zamora I
Drug Metab Dispos; 2008 Nov; 36(11):2199-210. PubMed ID: 18725510
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of N-substituted 7-methoxy-4-(aminomethyl) -coumarins by cytochrome P450 2D6 mutants and the indication of additional substrate interaction points.
Keizers PH; Van Dijk BR; De Graaf C; Van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN
Xenobiotica; 2006 Sep; 36(9):763-71. PubMed ID: 16971342
[TBL] [Abstract][Full Text] [Related]
6. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
Guengerich FP; Hanna IH; Martin MV; Gillam EM
Biochemistry; 2003 Feb; 42(5):1245-53. PubMed ID: 12564927
[TBL] [Abstract][Full Text] [Related]
7. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
[TBL] [Abstract][Full Text] [Related]
8. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen.
Dong H; Haining RL; Thummel KE; Rettie AE; Nelson SD
Drug Metab Dispos; 2000 Dec; 28(12):1397-400. PubMed ID: 11095574
[TBL] [Abstract][Full Text] [Related]
9. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
10. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
11. Effects of cytochrome P450 inhibitors on the biotransformation of fluorogenic substrates by adult male rat liver microsomes and cDNA-expressed rat cytochrome P450 isoforms.
Makaji E; Trambitas CS; Shen P; Holloway AC; Crankshaw DJ
Toxicol Sci; 2010 Feb; 113(2):293-304. PubMed ID: 19858067
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of dextromethorphan in human liver microsomes: a rapid HPCL assay to monitor cytochrome P450 2D6 activity.
Vielnascher E; Spatzenegger M; Mayrhofer A; Klinger P; Jäger W
Pharmazie; 1996 Aug; 51(8):586-8. PubMed ID: 8794469
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of coumarin-based fluorogenic P450 BM3 substrates and prospects for competitive inhibition screenings.
Neufeld K; Zu Berstenhorst SM; Pietruszka J
Anal Biochem; 2014 Jul; 456():70-81. PubMed ID: 24708937
[TBL] [Abstract][Full Text] [Related]
14. Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine.
Staack RF; Theobald DS; Paul LD; Springer D; Kraemer T; Maurer HH
Drug Metab Dispos; 2004 Apr; 32(4):379-81. PubMed ID: 15039289
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
Di L; Kerns EH; Li SQ; Carter GT
Int J Pharm; 2007 Apr; 335(1-2):1-11. PubMed ID: 17137735
[TBL] [Abstract][Full Text] [Related]
16. Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
Kemp CA; Flanagan JU; van Eldik AJ; Maréchal JD; Wolf CR; Roberts GC; Paine MJ; Sutcliffe MJ
J Med Chem; 2004 Oct; 47(22):5340-6. PubMed ID: 15481972
[TBL] [Abstract][Full Text] [Related]
17. Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes.
Favreau LV; Palamanda JR; Lin CC; Nomeir AA
Drug Metab Dispos; 1999 Apr; 27(4):436-9. PubMed ID: 10101136
[TBL] [Abstract][Full Text] [Related]
18. Kinetic deuterium isotope effects for 7-alkoxycoumarin O-dealkylation reactions catalyzed by human cytochromes P450 and in liver microsomes. Rate-limiting C-H bond breaking in cytochrome P450 1A2 substrate oxidation.
Kim KH; Isin EM; Yun CH; Kim DH; Guengerich FP
FEBS J; 2006 May; 273(10):2223-31. PubMed ID: 16649998
[TBL] [Abstract][Full Text] [Related]
19. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
20. Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6.
Keizers PH; Schraven LH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; van Dijk BR; Vermeulen NP; Commandeur JN
Biochem Biophys Res Commun; 2005 Dec; 338(2):1065-74. PubMed ID: 16269134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
